Background Epileptic seizures are neurological disorders common in children; 4 to 10 % of under 16-year olds have suffered at least one seizure. Antiepileptic drugs represent the basis of treatment for the majority of patients, but many of the drugs prescribed to pediatrics are used unlicensed and off-label. Objective To analyze the prevalence of use of unlicensed and off-label antiepileptic drugs, by the pediatric population, according to the Food and Drug Administration and the Brazilian National Health Surveillance Agency. Setting General Hospital of the Faculty of Medicine at Ribeirão Preto, Brazil. Methods A cross-sectional, retrospective and observational study was carried out. The daily prescriptions of children up to 12 years of age were collected for the analysis of antiepileptic drug use. Data of the registration number, sex, age, reason hospitalized, unit where hospitalized, drug prescribed, dosage, route and administration frequency were collected. Main outcome measure Antiepileptic drugs prescribed for children were classified as unlicensed and off-label according to the term of the product’s license registered in the Food and Drug Administration and the Brazilian National Health Surveillance Agency. Results Of the 6,637 pediatric patients identified during the study period, 583 (9.0 %) received at least one antiepileptic drug. The most used antiepileptic drugs were phenobarbital, phenytoin, carbamazepine, valproic acid and clonazepam. As expected, the number of pharmaceutical dosage form classified as unlicensed or off-label was high in both agencies, but distinct between the two. The number of patients (n = 287) using unlicensed drugs was similar in the two agencies, but the use of off-label drugs was higher according to the analysis carried out by the North American agency (40.5 %). Conclusions Old-generation antiepileptic drugs are widely prescribed to children. The results found for the use of off-label drugs demonstrate the absence of uniformity in action between the agencies and a lack of integration between the studies carried out. Although legislation on the licensing of drugs aims to protect the patients from drugs that have not been scientifically evaluated, the scarcity of data about the safety of the therapeutic resources obliges the doctors to prescribe unlicensed and off-label antiepileptic drugs to the pediatric population.
Antiepileptic drugs Brazilian National Health Surveillance Agency Brazil Children Food and Drug Administration Off-label use Unlicensed use
This is a preview of subscription content, log in to check access.
The authors would like to thank the directors of the General Hospital of the Faculty of Medicine at Ribeirão Preto of the University of São Paulo (HCFMRP-USP) for their assistance in data collection.
The study was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Choonara I, Conroy S. Unlicensed and off-label drug use in children—implications for safety. Drug Saf. 2002;25:1–5.PubMedCrossRefGoogle Scholar
Conroy S. Unlicensed and off-label drug use—issues and recommendations. Paediatr Drugs. 2002;4:353–9.PubMedGoogle Scholar
Hanssens Y, Deleu D, Al Balushi K, Al Hashar A, Al-Zakwani I. Drug utilization pattern of anti-epileptic drugs: a pharmacoepidemiologic study in Oman. J Clin Pharm Ther. 2002;27:357–64.PubMedCrossRefGoogle Scholar
Kimland E, Nydert P, Odlind V, Böttiger Y, Lindemalm S. Pediatric drug use with focus on off-label prescriptions at Swedish hospital—a nationwide study. Acta Paediatr. 2012;101:1–7.CrossRefGoogle Scholar
Morales-Carpi C, Estañ L, Rubio E, Lurbe E, Morales-Olivas FJ. Drug utilization and off-label drug use among Spanish emergency room pediatric patients. Eur J Clin Pharmacol. 2010;66:315–20.PubMedCrossRefGoogle Scholar
Clarkson A, Choonara I. Surveillance for fatal suspected adverse drug reaction in the UK. Arch Dis Child. 2002;87:462–7.PubMedCrossRefGoogle Scholar
Chen LC, Chen YF, Yang LL, Chou MH, Lin MF. Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan—a pharmaco-epidemiologic study. J Clin Pharm Ther. 2000;25:125–9.PubMedCrossRefGoogle Scholar
Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ. 1998;316:343–5.PubMedCrossRefGoogle Scholar
Abasolo-Osinaga E, Abecia-Inchaurregui LC, Etxeandia-Ikobaltzeta I, Burgos-Alonso N, Pozo JG. Estudio farmacoepidemiológico del consumo de fármacos antiepilépticos (1992–2004). Rev Neurol. 2008;46:449–53.PubMedGoogle Scholar
Glauser T, Ben-Menachem E, Borgeous B, Cnaan A, Chadwick D, Guerreiro C, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2006;47:1094–120.PubMedCrossRefGoogle Scholar
Abend NS, Gutierrez-Colina AM, Dlugos DJ. Medical treatment of pediatric status epileptics. Semin Pediatr Neurol. 2010;17:169–75.PubMedCrossRefGoogle Scholar
Nicholas JM, Ridsdale L, Richardson MP, Ashworth M, Gulliford MC. Trends in antiepileptic drug utilisation in UK primary care 1993–2008: cohort study using the general practice research database. Seizure. 2012;21(6):466–70.PubMedCrossRefGoogle Scholar
Perucca E. Clinically relevant drug interaction with antiepileptic drugs. Br J Clin Pharmacol. 2005;61:246–55.CrossRefGoogle Scholar
Johannessen SI, Landmark CJ. Antiepileptic drug interactions—principles and clinical implications. Curr Neuropharmacol. 2010;8:254–67.PubMedCrossRefGoogle Scholar
Yi ZM, Zhai SD, Huang S, Wang TS, Liu F. Off-label prescriptions for adult neurological patients: a pilot survey in China. Int J Clin Pharm. 2012;34(1):81–7.PubMedCrossRefGoogle Scholar
Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off-label drug use in paediatric wards in European countries. BMJ. 2000;7227(320):79–82.CrossRefGoogle Scholar
Shah SS, Goodman D, Feur P, Sharma V, Fargason C Jr, Hyman D, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–90.PubMedCrossRefGoogle Scholar
Dell’Aera M, Gasbarro AR, Padovano M, Laforgia N, Capodiferro D, Solarino B, et al. Unlicensed and off-label use of medicines at a neonatology clinic in Italy. Pharm World Sci. 2007;29(4):361–7.PubMedCrossRefGoogle Scholar
Di Paolo ER, Stoetter H, Cotting J, Frey P, Gehri M, Beck-Popovic M, et al. Unlicensed and off-label drug use in a Swiss pediatric university hospital. Swiss Med Wkly. 2006;136:218–22.PubMedGoogle Scholar
‘t Jong GW, van der Linden PD, Bakker EM, van der Lely N, Eland IA, Stricker BH, van den Anker JN. Unlicensed and off-label use in a pediatric ward of a general hospital in the Netherlands. Eur J Clin Pharmacol. 2002;58:293–7.PubMedCrossRefGoogle Scholar
Schirm E, Tobi H, Berg LTWJ. Risk factor for unlicensed and off-label drug use in children outside the hospital. Pediatrics. 2003;111:291–5.PubMedCrossRefGoogle Scholar